Pembrolizumab in Combination With Radiotherapy in Locally Advanced Non-Small Cell Lung Cancer (NSCLC)

NCT03245177 | Withdrawn Phase 1 DMC

• 1 other identifier: CFTSp103
• Study Type: interventional
• Target: N/A
• Locations: 0 countries
• Sites: N/A

Brief Summary

Lung cancer is the leading cause of cancer mortality worldwide and in the U.K alone; there are 38,000 new cases of non-small cell lung cancer (NSCLC) a year. The new treatment being tested in this study is called pembrolizumab, this is a type of immunotherapy, which works by stimulating the body's own immune system to fight cancer cells. Pembrolizumab blocks a protein on the T-cell surface (one of the cells of the immune system), which then triggers the cell to find and kill cancer cells. This will be given with radiotherapy to see if this combination is safe and effective at treating patients with non-small cell lung cancer. Pembrolizumab has proved to be a safe and effective treatment for other cancers such as melanoma and lung cancer. Radiotherapy is often given as standard treatment to treat lung cancer, and is proven to be a safe and tolerable treatment. However, the safety of the combination of Pembrolizumab and thoracic radiotherapy delivered concurrently has not been tested yet prospectively

Conditions

Non Small Cell Lung Cancer

Outcome Measures

Primary Outcomes (2)

• Recommended phase II dose (RP2D)

  The dose level at which \< 2/6 participants experience dose limiting toxicity (DLT).

  Within the period from the start of treatment until 12 weeks after completion of combined pembrolizumab and thoracic radiotherapy

• Dose limiting toxicity

  Non-haematologic: Any ≥grade 3 non-haematological toxicity definitely, probably or possibly related to the combination of Pembrolizumab and thoracic radiotherapy including: * Increased MRC dyspnoea score \>2 grades from baseline or CTCAE dyspnoea grade ≥3 persisting for \>7 days * Pneumonitis grade ≥4, or grade ≥3 persisting for \>7 days despite optimal medical management. * Oesophagitis grade ≥4, or ≥3 persisting for \>7 days despite optimal medical management * Toxicity leading to interruption of radiotherapy for \>4 days. Any grade 4 toxicity that has not previously been reported with pembrolizumab and is considered at least possibly related to the combination of pembrolizumab with radiotherapy Haematologic: * Neutropenia ≥grade 3 with fever \>38.5 * Thrombocytopaenia ≥grade 4. Any other event, in the opinion of the Safety Review Committee, is considered to be clinically significant and related to trial treatment.

  Within the period from the start of treatment until 12 weeks after completion of combined pembrolizumab and thoracic radiotherapy.

Secondary Outcomes (7)

• Safety profile, based on the occurrence of SAEs, SARs and SUSARs

  Until 90 days after participant completes study treatment. Assessed up to 17 months.

• Toxicity profile, based on the occurrence of adverse events, as assessed by CTCAE v4.0

  Until 30 days after participant completes study treatment. Assessed up to 15 months.

• Treatment compliance of Pembrolizumab combined with thoracic RT

  Until end of treatment for each participant.

• Best overall response to Pembrolizumab combined with thoracic RT (RECIST)

  Assessed for each participant from the start of the treatment until disease progression/recurrence. Assessed up to 15 months

• Best overall response to Pembrolizumab combined with thoracic RT (immune-related response

  Assessed for each participant from the start of the treatment until disease progression/recurrence. Assessed up to 15 months

Other Outcomes (3)

• Baseline biopsy expression level of the immunological checkpoint PD-L1

  Assessed for each participant at time of registration to the trial

• Change in PD-L1 expression level following Pembrolizumab combined with thoracic RT

  Assessed for each participant from the start of the treatment until disease progression/recurrence. Assessed up to 15 months

• Immune monitoring of primary tumour and peripheral blood mononuclear cells

  Assessed for each participant from the start of the treatment until disease progression/recurrence. Assessed up to 15 months

Study Arms (1)

Pembrolizumab plus radiotherapy

EXPERIMENTAL

Pembrolizumab is given by intravenous infusion over 30 minutes at a maximum dose of 200mg. The first dose of pembrolizumab is administered 14 days prior to the initiation of radiotherapy and every 3 weeks thereafter. Radiotherapy is given as a standard dose (60-66 Gy in 2 Gy/fraction) over 40-45 days (daily on Mon-Fri) Following completion of radiotherapy, participants will continue to receive pembrolizumab every 3 weeks for up to 12 months of maintenance treatment.

Biological: Pembrolizumab; Radiation: Radiotherapy

Interventions

Pembrolizumab BIOLOGICAL

Anti-PD-1 antibody

Pembrolizumab plus radiotherapy

Radiotherapy RADIATION

60-66 Gy in 30-33 fractions, 2 Gy per fraction

Pembrolizumab plus radiotherapy

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Histologically or cytologically confirmed NSCLC
• Unresectable stage III NSCLC not suitable for concurrent chemoradiotherapy i.e;
• Patient unsuitable for cisplatin (eg poor renal function);
• Large volume of disease with predicted dose to thoracic organs at risk that are likely to exceed the constraints for concurrent chemoradiotherapy, in the opinion of a clinical oncologist specialised in lung cancer
• Stage IV NSCLC with dominant chest symptoms and low burden of metastatic disease who may benefit from thoracic RT
• Patient considered suitable for radical radiotherapy
• If chemotherapy has been given previously, the maximum interval between the last day of chemotherapy and the start of radiotherapy must be 6 weeks. The minimum interval between the last day of chemotherapy and the start of Pembrolizumab must be one week
• Age ≥ 18
• Life expectancy estimated to be greater than 6 months
• Performance status (ECOG) 0 or 1 (see Appendix 1)
• MRC dyspnoea score \< 3 (see Appendix 2)
• FEV1 ≥ 40% predicted and DLCO ≥ 40% predicted; Lung V20 ≤ 30% in the dose finding part of the study and ≤ 35% in the expanded cohort
• No prior thoracic radiotherapy (excluding patients that have had RT for Breast cancer providing that the overlap is minimal as per local investigators discretion or as discussed and agreed by CI as required) or T cell modulating antibodies (including anti-PD-1, anti-PD-L1, PD-L2, anti-CD137 and anti-CTLA4, including ipilimumab or any other antibody or drug specifically targeting T-cell co-stimulation or checkpoint pathways)
• Measurable disease based on RECIST 1.1
• Patient willing to undergo a repeat biopsy post RT

You may not qualify if:

• Mixed non-small cell and small cell tumours
• Participation in a study of an investigational agent or using an investigational device within 4 weeks prior to the anticipated start of treatment.
• Current or previous malignant disease within 3 years except CIN, non-melanoma skin cancer and low grade, low stage prostate cancer found as incidental finding and not requiring treatment
• History of interstitial pneumonitis (to include diffuse alveolar damage, non-malignant causes of pneumonitis, acute respiratory distress syndrome, alveolitis, cryptogenic organising pneumonia, obliterative bronchiolitis, non-malignant causes of pulmonary fibrosis)
• Presence of brain metastases confirmed by CT or MR brain (unless suitable for local treatment such as SRS or Neurosurgery)
• History of autoimmune disease requiring steroids or immunosuppressive medication
• Uncontrolled hypothyroidism or hyperthyroidism
• Other diseases requiring immunosuppressive therapy greater than 28 days prior to the anticipated first dose of trial treatment.
• Other diseases requiring systemic glucocorticoid (doses \<=10 mg prednisolone or equivalent) prior to the first dose of trial treatment.
• Received a prior autologous or allogeneic organ or tissue transplantation.
• Chronic GI disease likely to interfere with protocol treatment.
• Testing positive for human immunodeficiency virus, active hepatitis B or C infection.
• Treatment with live vaccine within 30 days prior to the first dose of trial treatment.
• Patients of reproductive potential who are unable to comply with effective contraception if sexually active during the study and for up to 120 days after the last dose of Pembrolizumab
• Women who are pregnant or breastfeeding. Women of childbearing potential must have a negative serum or urine pregnancy test

Sponsors & Collaborators

• Prof Corinne Faivre-Finn: lead
• University of Leeds: collaborator
• Merck Sharp & Dohme LLC: collaborator
• Cancer Research UK: collaborator

MeSH Terms

Conditions

Carcinoma, Non-Small-Cell Lung

Interventions

pembrolizumab; Radiotherapy

Condition Hierarchy (Ancestors)

Carcinoma, Bronchogenic; Bronchial Neoplasms; Lung Neoplasms; Respiratory Tract Neoplasms; Thoracic Neoplasms; Neoplasms by Site; Neoplasms; Lung Diseases; Respiratory Tract Diseases

Intervention Hierarchy (Ancestors)

Therapeutics

Study Officials

• Corinne Faivre-Finn

  The Christie NHS Foundation Trust and the University of Manchester

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: interventional
• Phase: phase 1
• Allocation: NA
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: SINGLE GROUP
• Sponsor Type: OTHER
• Responsible Party: SPONSOR INVESTIGATOR
• PI Title: Professor of Thoracic Radiation Oncology & Honorary Consultant Clinical Oncology

Study Record Dates

• First Submitted: July 13, 2017
• First Posted: August 10, 2017
• Study Start: August 1, 2017
• Primary Completion: August 1, 2019
• Study Completion: August 1, 2019
• Last Updated: July 28, 2021

Record last verified: 2021-07

Data Sharing

• IPD Sharing: Will not share